What Is the Difference Between BPC-157 and TB-500?

BPC-157 and TB-500 start from different proteins and point at different repair steps. BPC-157 is a 15 amino acid piece of a stomach juice protein that researchers link to blood vessel and tendon cell signals. TB-500 is a lab made piece of thymosin beta-4, a 43 amino acid protein found in most cells that researchers link to cell movement. Rat and mouse work shows faster tendon outgrowth and wound closure, but neither has finished a large human trial for muscle or joint injuries.

Where do they come from and how do they work

BPC-157 copies part of a protective protein found in human stomach juice. It dissolves in water and stayed stable in stomach acid for at least 24 hours in lab tests rat tendon study. Researchers propose it supports repair by turning on a vessel growth signal called VEGFR2 through Akt-eNOS, which raises nitric oxide, a molecule that helps blood flow, and wakes up fibroblasts, the cells that build tendon tissue. A review notes this activity looked strongest in animal models of poorly supplied tissue like tendons BPC-157 review.

TB-500 copies the actin binding part of thymosin beta-4 Superpower guide. Actin is the inner scaffolding that lets a cell change shape and crawl. By holding the building block form of actin, TB-500 may help skin cells and vessel lining cells move into a damaged area and form new vessels. A lab study found a seven amino acid actin binding spot carried almost the same vessel sprouting and cell movement activity as the full thymosin beta-4 protein actin-motif study.

What have studies shown

In rats with cut Achilles tendons, BPC-157 sped healing through tendon outgrowth, cell survival and cell migration rat tendon study. In people, only three small pilot studies exist, for knee pain, bladder irritation and vein safety testing, with no adverse effects reported in those pilots and no large trials BPC-157 review.

Thymosin beta-4 sped wound repair, new vessel growth and hair growth in normal and older rodents through more cell migration and vessel formation rodent wound study. Human work on this family centers on eye and skin wounds. Direct TB-500 results are limited to lab screening for breakdown products and fibroblast movement in dishes, not long term muscle or tendon repair in animals or people 2026 thymosin beta-4 review.

Are they proven or allowed for injuries

Neither has completed a human efficacy trial for musculoskeletal use. Both sit in FDA 503A Category 2 for bulk substances and both appear on the WADA Prohibited List, so competitive athletes face a ban Superpower guide. FDA also lists the TB-500 related fragment LKKTETQ among bulk substances that may carry a significant safety risk in compounding because human exposure data are limited 2026 thymosin beta-4 review.